nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.01.2016 | Research Paper

Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer

verfasst von: Shanna A. Arnold, Holli A. Loomans, Tatiana Ketova, Claudia D. Andl, Peter E. Clark, Andries Zijlstra

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The extracellular matrix protein fibronectin (FN) contributes to the structural integrity of tissues as well as the adhesive and migratory functions of cells. While FN is abundantly expressed in adult tissues, the expression of several alternatively spliced FN isoforms is restricted to embryonic development, tissue remodeling and cancer. These FN isoforms, designated ED-A and ED-B, are frequently expressed by cancer cells, tumor-associated fibroblasts and newly forming blood vessels. Using a highly sensitive collagen-based indirect ELISA, we evaluated the correlation of urinary ED-A and ED-B at time of cystectomy with overall survival in patients with high-grade bladder cancer (BCa). Detectable levels of total FN as well as ED-A and ED-B were found in urine from 85, 73 and 51 % of BCa patients, respectively. The presence of urinary ED-A was a significant independent predictor of 2-year overall survival (OS) after adjusting for age, tumor stage, lymph node stage, and urinary creatinine by multivariable Logistic Regression (p = 0.029, OR = 4.26, 95 % CI 1.16–15.71) and improved accuracy by 3.6 %. Furthermore, detection of ED-A in the urine was a significant discriminator of survival specifically in BCa patients with negative lymph node status (Log-Rank, p = 0.006; HR = 5.78, 95 % CI 1.39–24.13). Lastly, multivariable Cox proportional hazards analysis revealed that urinary ED-A was an independent prognostic indicator of 5-year OS rate for patients with BCa (p = 0.04, HR = 2.20, 95 % CI 1.04–4.69). Together, these data suggest that cancer-derived, alternatively spliced FN isoforms can act as prognostic indicators and that additional studies are warranted to assess the clinical utility of ED-A in BCa.

Nur mit Berechtigung zugänglich

Potts JR, Campbell ID (1996) Structure and function of fibronectin modules. Matrix Biol 15:313–320CrossRefPubMed

To WS, Midwood KS (2011) Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair 4:21PubMedCentralCrossRefPubMed

Tamkun JW, Hynes RO (1983) Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem 258(7):4641–4647PubMed

Mosher DF (2006) Plasma fibronectin concentration: a risk factor for arterial thrombosis? Arterioscler Thromb Vasc Biol 26(6):1193–1195CrossRefPubMed

Ting KM et al (2000) Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. J Investig Dermatol 114:706–711CrossRefPubMed

Matsuura H, Hakomori S (1985) The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. PNAS 82(19):6517–6521PubMedCentralCrossRefPubMed

Borsi L et al (1987) Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol 104(3):595–600CrossRefPubMed

Carnemolla B et al (1989) A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 108(3):1139–1148CrossRefPubMed

Glukhova MA et al (1990) Expression of fibronectin variants in vascular and visceral smooth muscle cells in development. Dev Biol 141(1):193–202CrossRefPubMed

10.

Castellani P et al (1986) Transformed human cells release different fibronectin variants than do normal cells. J Cell Biol 103(5):1671–1677CrossRefPubMed

11.

Zardi L et al (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 6(8):2337–2342PubMedCentralPubMed

12.

D’Ovidio MC et al (1998) Intratumoral microvessel density and expression of ED-A/ED-B sequences of fibronectin in breast carcinoma. Eur J Cancer 34(7):1081–1085CrossRefPubMed

13.

Rybak J-N et al (2007) The extra-domain a of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 67(22):10948–10957CrossRefPubMed

14.

Manabe R-I et al (1997) Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol 139(1):295–307PubMedCentralCrossRefPubMed

15.

Nicolo G et al (1990) PII: 0922–3371(90), 90056–3. Cell Differ Dev 32:401–408CrossRefPubMed

16.

Pujuguet P et al (1996) Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer contribution of cancer cells and tumor-associated myofibroblasts. Am J Pathol 148(2):579–592PubMedCentralPubMed

17.

Kohan M et al (2010) EDA-containing cellular fibronectin induces fibroblast differentiation through binding to α4β7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J 24(11):4503–4512CrossRefPubMed

18.

Manabe R, Oh-e N, Sekiguchi K (1999) Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem 274(9):5919–5924CrossRefPubMed

19.

Booth AJ et al (2012) Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol 226(4):609–618PubMedCentralCrossRefPubMed

20.

Khan MM et al (2012) Alternatively-spliced extra domain A of fibronectin promotes acute inflammation and brain injury after cerebral ischemia in mice. Stroke 43(5):1376–1382PubMedCentralCrossRefPubMed

21.

McFadden JP et al (2010) Psoriasis and extra domain A fibronectin loops. Br J Dermatol 163(1):5–11PubMed

22.

Castellani P et al (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer J Int Du Cancer 59(5):612–618CrossRef

23.

Khan ZA et al (2005) EDB fibronectin and angiogenesis—a novel mechanistic pathway. Angiogenesis 8(3):183–196CrossRefPubMed

24.

Astrof S et al (2004) Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol Cell Biol 24(19):8662–8670PubMedCentralCrossRefPubMed

25.

Chen W, Culp LA (1996) Adhesion mediated by fibronectin’s alternatively spliced EDb (EIIIB) and its neighboring type III repeats. Exp Cell Res 223(1):9–19CrossRefPubMed

26.

Carnemolla B et al (1992) The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem 267(34):24689–24692PubMed

27.

Schiefner A, Gebauer M, Skerra A (2012) Extra-domain B in oncofetal fibronectin structurally promotes fibrillar head-to-tail dimerization of extracellular matrix protein. J Biol Chem 287(21):17578–17588PubMedCentralCrossRefPubMed

28.

Ioachim E et al (2005) A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 95(4):655–659CrossRefPubMed

29.

Yang X et al (2013) Diagnostic value of bladder tumor fibronectin in patients with bladder tumor: a systematic review with meta-analysis. Clin Biochem 46(15):1377–1382CrossRefPubMed

30.

Fernandez-Garcia B et al (2014) Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology 64(4):512–522CrossRefPubMed

31.

Ma LJ et al (2014) Fibronectin overexpression is associated with latent membrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma. Tumour Biol 35(2):1703–1712CrossRefPubMed

32.

Inufusa H et al (1995) Localization of oncofetal and normal fibronectin in colorectal cancer correlation with histologic grade, liver metastasis, and prognosis. Cancer 75(12):2802–2808CrossRefPubMed

33.

Ylätupa S et al (1995) An improved method for quantification of extra domain A-containing cellular fibronectin (EDAcFN) in different body fluids. Clin Chim Acta 234:79–90CrossRefPubMed

34.

Hegele A et al (2003) Cellular fibronectin in patients with transitional cell carcinoma of the bladder. Urol Res 30(6):363–366PubMed

35.

Richter P et al (2008) IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC). J Cancer Res Clin Oncol 134(10):1059–1065CrossRefPubMed

36.

Blick CGT et al (2011) Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int 110(1):84–94CrossRefPubMed

37.

Planz B et al (2005) The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol 31(3):304–308CrossRefPubMed

38.

Alias-Melgar A et al (2013) Association of urine oncofetal fibronectin levels with urology's most common disorders. Ann Clin Lab Sci 43(4):420–423PubMed

39.

Eissa SS et al (2002) Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 168(2):465–469CrossRefPubMed

40.

Katayama M et al (1991) Urinary fibronectin fragments (a potential tumor marker) measured by immunoenzymometric assay with domain-specific monoclonal antibodies. Clin Chem 37(3):466–471PubMed

41.

Malmström PU et al (1993) Increasing survival of patients with urinary bladder cancer. A nationwide study in Sweden 1960–1986. Eur J Cancer 29A(13):1868–1872CrossRefPubMed

42.

Saito M et al (2005) Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur Urol 48(5):865–871CrossRefPubMed

43.

Eissa SS et al (2011) The clinical relevance of urine-based markers for diagnosis of bladder cancer. Med Oncol 28(2):513–518CrossRefPubMed

44.

Shiozawa K, Hino K, Shiozawa S (2001) Alternatively spliced EDA-containing fibronectin in synovial fluid as a predictor of rheumatoid joint destruction. Rheumatology 40(7):739–742CrossRefPubMed

45.

Engvall E, Ruoslahti E (1977) Binding of soluble form of fibroblsat surface protein, fibronectin, to collagen. Int J Cancer 20:1–5CrossRefPubMed

46.

Engvall E, Ruoslahti E, Miller EJ (1978) Affinity of fibronectin to collagens of different genetic types and to fibrinogen. J Exp Med 8:1–12

47.

Menzin AW et al (1998) Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants. Cancer 82:152–158CrossRefPubMed

48.

Menéndez V et al (2005) Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology 65(2):284–289CrossRefPubMed

49.

Witjes JA, Moonen PMJ, van der Heijden AG (2005) Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study. Eur Urol 47(3):319–322CrossRefPubMed

50.

Otto W et al (2013) Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of Ki-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients. Clin Genitourin Cancer 11(4):537–544CrossRefPubMed

51.

Riester M et al (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18(5):1323–1333PubMedCentralCrossRefPubMed

52.

Tarin TV et al (2012) Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol 61(5):1025–1030PubMedCentralCrossRefPubMed

53.

Eissa S et al (2010) Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol 27(4):1286–1294CrossRefPubMed

54.

Bellmunt J et al (2006) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18(3):522–528CrossRef

55.

Borsi L, Balza E, Allemanni G, Zardi L (1992) Differential expression of the fibronectin isoform containing the ED-B oncofetal domain in normal human fibroblast cell lines originating from different tissues. Exp Cell Res 199:98–105CrossRefPubMed

56.

Barone MV, Henchcliffe C, Baralle FE, Paolella G (1989) Cell type specific trans-acting factors are involved in alternative splicing of human fibronectin pre-mRNA. EMBO J Eur Mol Biol Organ 8:1079–1085

57.

Zijlstra A, McCabe NR, Schelling ME (1999) Expression and assembly of the angiogenic marker B-fibronectin by endothelial cells in vitro: regulation by confluency. Angiogenesis 3:77–87CrossRefPubMed

Titel: Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer
verfasst von: Shanna A. Arnold
Holli A. Loomans
Tatiana Ketova
Claudia D. Andl
Peter E. Clark
Andries Zijlstra
Publikationsdatum: 01.01.2016
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 1/2016
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-015-9754-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Tip60 regulates MT1-MMP transcription and invasion of glioblastoma cells through NF-κB pathway

Retirement of Professor Sue Eccles as Editor-in-Chief (Europe)

Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis

Potent anti-tumor effects of EGFR-targeted hybrid peptide on mice bearing liver metastases

S100A11 is a potential prognostic marker for clear cell renal cell carcinoma

Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie